Atropine
Also sold as: Donnatal, Atropen, Lomotil, Isopto Atropine, Motofen (+3 more)
Related Medications
These drugs share a pharmacologic classification but are NOT interchangeable. Listing here does not imply clinical equivalence. A physician must evaluate each drug individually for the patient's specific condition.
Classification: Cholinergic Muscarinic Antagonists (source: RxClass/NLM)
- tropicamideAnticholinergicSame Class
- aclidiniumAnticholinergicSame Class
- benztropineAnticholinergicSame Class
- umeclidiniumAnticholinergicSame Class
- glycopyrroniumAnticholinergicSame Class
- revefenacinAnticholinergicSame Class
- clidiniumAnticholinergicSame Class
- dicyclomineAnticholinergicSame Class
- tiotropiumAnticholinergicSame Class
- ipratropiumAnticholinergicSame Class
- methscopolamineAnticholinergicSame Class
- scopolamineAnticholinergicSame Class
- tolterodineCholinergic Muscarinic AntagonistSame Class
- darifenacinCholinergic Muscarinic AntagonistSame Class
- trospiumCholinergic Muscarinic AntagonistSame Class
Insurance Coverage User-Reported
No community coverage data yet for atropine.
Coverage data submission coming soon.
Drug Information
Indications & Uses
1 INDICATIONS & USAGE Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.
Dosage & Administration
2 DOSAGE & ADMINISTRATION 2.1 General Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless solution is clear and seal is intact. Each vial is intended for single dose only. Discard unused portion. For Intravenous administration. Titrate based on heart rate, PR interval, blood pressure and symptoms. 2.2 Adult Dosage 2.3 Pediatric Dosage Dosing in pediatric populations has not been well studied. Usual initial dose is 0.01 to 0.03 mg/kg. 2.4 Dosing in Patients with Coronary Artery Disease Limit the total dose of atropine sulfate to 0.03 to 0.04 mg/kg [see WARNINGS AND PRECAUTIONS (5.1 )]. DOSAGE
Side Effects (Adverse Reactions)
6 ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of atropine sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Most of the side effects of atropine are directly related to its antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur. Anhidrosis can produce heat intolerance. Constipation and difficulty in micturition may occur in elderly patients. Occasional hypersensitivity reactions have been observed, especially skin rashes which in some instances progressed to exfoliation.
Drug Interactions
7 DRUG INTERACTIONS 7.1 Mexiletine Atropine Sulfate Injection decreased the rate of mexiletine absorption without altering the relative oral bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and intravenous metoclopramide during pretreatment for anesthesia.
Contraindications
4 CONTRAINDICATIONS None.
Verify with Primary Sources
Always verify clinical information with authoritative sources.
Medical Disclaimer: Information on this page is sourced from FDA-approved labeling data and is for educational reference only. It does not constitute medical advice. This information does not establish a provider-patient relationship. Always verify with current prescribing information and consult a licensed healthcare professional before any clinical decision. Read full disclaimer.
Data sourced from RxNorm (NLM/NIH), FDA Orange Book, OpenFDA, DailyMed. Last updated: 2026-03-02.